Wounds – Pipeline Review, H1 2013

Published: April 2013
No. of Pages: 197
  

Global Markets Direct’s, ''Wounds Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Wounds, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wounds. Wounds Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Wounds.
  • A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Wounds pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Wounds.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Wounds – Pipeline Review, H1 2013

Table Of Contents

Table Of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Wounds Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Wounds 11
Wounds Therapeutics under Development by Companies 13
Wounds Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Wounds Therapeutics – Products under Development by Companies 24
Wounds Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Wounds Therapeutics Development 30
Sanofi-Aventis 30
Biotec Pharmacon ASA 31
Pharming Group N.V. 32
Nanotherapeutics, Inc. 33
Octapharma AG 34
NexMed, Inc. 35
Bio3 Research S.r.l 36
NeoStem, Inc. 37
Hanall Pharmaceutical Co., Ltd. 38
Sucampo Pharmaceuticals, Inc. 39
Creative Antibiotics Sweden AB 40
CytoTools AG 41
MetrioPharm AG 42
DONGKOOK Pharmaceutical Co., Ltd. 43
AcelleRX Therapeutics Inc. 44
Healthpoint, Ltd. 45
Omnio Healer AB 46
ConjuGon, Inc. 47
Garnet BioTherapeutics 48
Gene Signal International SA. 49
Glycotex, Inc. 50
Destiny Pharma Ltd. 51
AndroScience Corporation 52
Polyphor Ltd. 53
Omeros Corporation 54
BRIDGE BIORESEARCH PLC 55
FirstString Research, Inc. 56
Molecular Design International, Inc. 57
Sirnaomics, Inc. 58
Theravasc, Inc. 59
Medistem, Inc. 60
Encore Therapeutics Inc. 61
ImmuneRegen BioSciences, Inc. 62
Ascenion GmbH 63
Pacific Northwest Biotechnology, LLC 64
Beech Tree Labs, Inc. 65
EyeGene, Inc. 66
Neumedicines Inc. 67
OmegaGenesis, Inc. 68
AlgiPharma AS 69
SomaGenics Inc. 70
Advancell 71
Birken GmbH 72
Wounds – Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 79
Recombinant Human Collagen Type 1 - Drug Profile 79
Homspera - Drug Profile 80
doxycycline - Drug Profile 82
POL-6326 - Drug Profile 83
CTR-2 - Drug Profile 85
cobiprostone - Drug Profile 86
alprostadil - Drug Profile 87
GLYC-101 - Drug Profile 90
GLYC-101 - Drug Profile 91
ASCJ-9 - Drug Profile 92
PXL-01 - Drug Profile 93
DermaPro CI-05 - Drug Profile 95
DermaPro CI-05 - Drug Profile 97
GS-156 - Drug Profile 99
JVS-100 - Drug Profile 100
GBT-009 - Drug Profile 102
Autologous Platelet Gel - Drug Profile 103
Soluble Beta Glucan - Drug Profile 104
KUR-211 - Drug Profile 107
BPM-31510 - Drug Profile 108
DAC N-055 - Drug Profile 110
ColMod - Drug Profile 111
adalimumab - Drug Profile 112
StrataGraft Skin Tissue - Drug Profile 113
KUR-212 - Drug Profile 115
STP-705 - Drug Profile 116
Streptolysin O - Drug Profile 117
MiR-27a Inhibitor - Drug Profile 118
NMIL-121 - Drug Profile 119
OleogelS-10 - Drug Profile 120
Vasculotide - Drug Profile 122
LL-37 - Drug Profile 123
AKB-4924 - Drug Profile 124
isoniazid - Drug Profile 125
HO/03/06 - Drug Profile 126
Neurotensin - Drug Profile 127
PPA-904 - Drug Profile 128
Bactericidal Venom-Based Polypeptides - Drug Profile 129
Granexin - Drug Profile 130
OTR-4120 - Drug Profile 131
VSEL for Chronic Wound Healing - Drug Profile 132
Nanorods Topical - Drug Profile 133
ropivacaine hydrochloride Extended Release - Drug Profile 134
metformin - Drug Profile 135
Angiostem Derivatives - Drug Profile 136
ANs-31 - Drug Profile 137
Drug Targeting LGR6 - Drug Profile 138
HL-156Fib - Drug Profile 139
AlloGraf - Drug Profile 140
Mesenchymal Cells - Drug Profile 141
ARA-290 - Drug Profile 142
B-4474 - Drug Profile 144
Drug For Gram Positive Wound Infections - Drug Profile 145
phenytoin - Drug Profile 146
HDFx - Drug Profile 147
XF-70 - Drug Profile 148
Drug For Debridement - Drug Profile 149
Wound Healing Program - Drug Profile 150
Non-Inflammatory Macrophages - Drug Profile 151
Drug For Wound Healing - Drug Profile 152
EG-Decorin - Drug Profile 153
Bismith-Thiol Compound For Acute Wound Infection - Drug Profile 154
Bismith-Thiol Compound For Chronic Wound Infection - Drug Profile 155
Umbilical Cord Blood-Derived Stem Cells - Drug Profile 156
Fibroblast Growth Factor Conjugate - Drug Profile 157
Drug For Wound Healing - Drug Profile 158
INP-11252 - Drug Profile 159
Matrix Metalloprotease Inhibitor - Drug Profile 160
Macrophage-Stimulating Lipopeptide - Drug Profile 161
Drug For Wound Healing - Drug Profile 162
Drug For Acute Wound Care - Drug Profile 163
KUR-213 - Drug Profile 164
CSTC-1 - Drug Profile 165
AG-30/5C - Drug Profile 166
Recombinant Plasminogen - Drug Profile 167
Recombinant Plasminogen - Drug Profile 168
Wounds Therapeutics – Drug Profile Updates 169
Wounds Therapeutics – Discontinued Products 183
Wounds Therapeutics - Dormant Products 184
Wounds – Product Development Milestones 187
Featured News & Press Releases 187
Appendix 191
Methodology 191
Coverage 191
Secondary Research 191
Primary Research 191
Expert Panel Validation 191
Contact Us 192
Disclaimer 192

List of Tables

Number of Products Under Development for Wounds, H1 2013 16
Products under Development for Wounds – Comparative Analysis, H1 2013 17
Number of Products under Development by Companies, H1 2013 19
Number of Products under Development by Companies, H1 2013 (Contd..1) 20
Number of Products under Development by Companies, H1 2013 (Contd..2) 21
Number of Products under Development by Companies, H1 2013 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2013 24
Comparative Analysis by Late Stage Development, H1 2013 25
Comparative Analysis by Mid Clinical Stage Development, H1 2013 26
Comparative Analysis by Early Clinical Stage Development, H1 2013 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 28
Products under Development by Companies, H1 2013 29
Products under Development by Companies, H1 2013 (Contd..1) 30
Products under Development by Companies, H1 2013 (Contd..2) 31
Products under Development by Companies, H1 2013 (Contd..3) 32
Products under Development by Companies, H1 2013 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2013 34
Sanofi-Aventis, H1 2013 35
Biotec Pharmacon ASA, H1 2013 36
Pharming Group N.V., H1 2013 37
Nanotherapeutics, Inc., H1 2013 38
Octapharma AG, H1 2013 39
NexMed, Inc., H1 2013 40
Bio3 Research S.r.l, H1 2013 41
NeoStem, Inc., H1 2013 42
Hanall Pharmaceutical Co., Ltd., H1 2013 43
Sucampo Pharmaceuticals, Inc., H1 2013 44
Creative Antibiotics Sweden AB, H1 2013 45
CytoTools AG, H1 2013 46
MetrioPharm AG, H1 2013 47
DONGKOOK Pharmaceutical Co., Ltd., H1 2013 48
AcelleRX Therapeutics Inc., H1 2013 49
Healthpoint, Ltd., H1 2013 50
Omnio Healer AB, H1 2013 51
ConjuGon, Inc., H1 2013 52
Garnet BioTherapeutics, H1 2013 53
Gene Signal International SA., H1 2013 54
Glycotex, Inc., H1 2013 55
Destiny Pharma Ltd., H1 2013 56
AndroScience Corporation, H1 2013 57
Polyphor Ltd., H1 2013 58
Omeros Corporation, H1 2013 59
BRIDGE BIORESEARCH PLC, H1 2013 60
FirstString Research, Inc., H1 2013 61
Molecular Design International, Inc., H1 2013 62
Sirnaomics, Inc., H1 2013 63
Theravasc, Inc., H1 2013 64
Medistem, Inc., H1 2013 65
Encore Therapeutics Inc., H1 2013 66
ImmuneRegen BioSciences, Inc., H1 2013 67
Ascenion GmbH, H1 2013 68
Pacific Northwest Biotechnology, LLC, H1 2013 69
Beech Tree Labs, Inc., H1 2013 70
EyeGene, Inc., H1 2013 71
Neumedicines Inc., H1 2013 72
OmegaGenesis, Inc., H1 2013 73
AlgiPharma AS, H1 2013 74
SomaGenics Inc., H1 2013 75
Advancell, H1 2013 76
Birken GmbH, H1 2013 77
Assessment by Monotherapy Products, H1 2013 78
Assessment by Stage and Route of Administration, H1 2013 80
Assessment by Stage and Molecule Type, H1 2013 83
Wounds Therapeutics – Drug Profile Updates 174
Wounds Therapeutics – Discontinued Products 188
Wounds Therapeutics – Dormant Products 189
Wounds Therapeutics – Dormant Products (Contd..1) 190
Wounds Therapeutics – Dormant Products (Contd..2) 191

List of Figures

Number of Products under Development for Wounds, H1 2013 16
Products under Development for Wounds – Comparative Analysis, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 23
Late Stage Products, H1 2013 25
Mid Clinical Stage Products, H1 2013 26
Early Clinical Stage Products, H1 2013 27
Discovery and Pre-Clinical Stage Products, H1 2013 28
Assessment by Monotherapy Products, H1 2013 78
Assessment by Route of Administration, H1 2013 79
Assessment by Stage and Route of Administration, H1 2013 80
Assessment by Molecule Type, H1 2013 81
Assessment by Stage and Molecule Type, H1 2013 82

Published By: Global Markets Direct
Product Code: Global Markets Direct5795


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100